Lipid-based nanoparticles for drug delivery in Parkinson’s disease
Open Access
- 1 January 2024
- journal article
- review article
- Published by Walter de Gruyter GmbH in Translational Neuroscience
- Vol. 15 (1) , 20220359
Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder that predominantly affects dopaminergic neurons in the substantia nigra and ventral tegmental area, resulting in symptoms such as tremors, muscle rigidity, bradykinesia, and potential cognitive and affective disturbances. The effective delivery of pharmacological agents to the central nervous system is hindered by various factors, including the restrictive properties of the blood‒brain barrier and blood‒spinal cord barrier, as well as the physicochemical characteristics of the drugs. Traditional drug delivery methods may not provide the therapeutic concentrations necessary for functional restoration in PD patients. However, lipid-based nanoparticles (NPs) offer new possibilities for enhancing the bioavailability of established treatment regimens and developing innovative therapies that can modify the course of the disease. This review provides a concise overview of recent advances in lipid-based NP strategies aimed at mitigating specific pathological mechanisms relevant to PD progression. This study also explores the potential applications of nanotechnological innovations in the development of advanced treatment modalities for individuals with PD.Keywords
This publication has 168 references indexed in Scilit:
- Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease (Adv. Mater. 51/2023)Advanced Materials, 2023
- A Triple Role for a Bilayer: Using Nanoliposomes to Cross and Protect Cellular MembranesThe Journal of Membrane Biology, 2021
- mRNA Delivery Using Bioreducible Lipidoid Nanoparticles Facilitates Neural Differentiation of Human Mesenchymal Stem CellsAdvanced Healthcare Materials, 2020
- Ultrasound‐triggered effects of the microbubbles coupled to GDNF‐ and Nurr1‐loaded PEGylated liposomes in a rat model of Parkinson's diseaseJournal of Cellular Biochemistry, 2018
- The Parkinson Pandemic—A Call to ActionJAMA Neurology, 2018
- Synthetic bioreducible lipid‐based nanoparticles for miRNA delivery to mesenchymal stem cells to induce neuronal differentiationBioengineering & Translational Medicine, 2016
- NGF, BDNF, NT3, and NT42014
- Oral Apomorphine Delivery from Solid Lipid Nanoparticles with Different Monostearate Emulsifiers: Pharmacokinetic and Behavioral EvaluationsJournal of Pharmaceutical Sciences, 2011
- Totipotency, Pluripotency and Nuclear Reprogramming2009
- Intravenous glial‐derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoterThe Journal of Gene Medicine, 2008